Dentons advises Vitrolife on €1.25 billion acquisition of Igenomix

Global law firm Dentons, at the request of Cedric Law, has advised Vitrolife on the acquisition of 100% of the share capital in Igenomix for €1.25 billion from EQT Fund

Dentons has advised Vitrolife AB, a Swedish multinational focused on medical devices for in vitro fertilization (IVF), on the acquisition of 100% of the share capital in Igenomix for €1.25 billion from EQT Fund, Charme Capital Partners and other shareholders. Igenomix is a global leader in women’s health and reproductive genetic testing services for IVF clinics.

The team from Dentons advising on the transaction was led by Nieves Briz (pictured), who is the firm’s Barcelona managing partner, and included a multi-competency, cross-border team. Briz was supported by partner Jesus Duran and counsel Natalia Ontiveros. The team also included from the Barcelona office associate Gabriel Mendez, junior associates Daniel Seculi and Angela de la Iglesia, and senior associates Iñigo Olarte and Adrien Coispel. From the Madrid office the team was made up of counsel Juan Alonso Berberena, and junior associates Sara Moukayed and Blanca Stolzenburg who performed the due diligence on the operation. Partner Michele Carpagnano (Rome) and associates Paloma Hurtado (Madrid) and Giulia Giordano (Rome) advised on Competition Law matters, including Merger Control and FDI screening.

This transaction will result in the creation of a global leader in reproductive health by combining the Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s IVF device portfolio, as well as the complementary knowledge and market presence of the two companies.

Lazard acted as financial adviser and Olof Thorsell from Cedric Law acted as legal adviser to Vitrolife AB.